(Q34008483)

30 July 2017

1 reference

title

The way forward in HCV treatment--finding the right path (English)

1 reference

30 July 2017

4

Stefan Zeuzem

1 reference

30 July 2017

3

Jürgen K Rockstroh

1 reference

30 July 2017

1

Michael P Manns

1 reference

30 July 2017

Graham R Foster

2

1 reference

30 July 2017

Fabien Zoulim

series ordinal

5

1 reference

30 July 2017

Michael Houghton

series ordinal

6

1 reference

30 July 2017

publication date

1 December 2007

1 reference

Nature Reviews Drug Discovery

30 July 2017

published in

1 reference

30 July 2017

volume

6

1 reference

30 July 2017

issue

12

1 reference

30 July 2017

page(s)

991-1000

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2411

30 July 2017

exact match

0 references

cites work

Epidemiology of hepatitis C virus (HCV) infection

1 reference

Treatment of chronic HCV infection in special populations

21 January 2018

1 reference

Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection.

21 January 2018

1 reference

Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models

21 January 2018

1 reference

Nucleoside analog inhibitors of hepatitis C virus replication

21 January 2018

1 reference

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease

21 January 2018

1 reference

HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase

21 January 2018

1 reference

Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine

21 January 2018

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

31 March 2020

1 reference

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

31 March 2020

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

31 March 2020

1 reference

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

31 March 2020

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C.

31 March 2020

1 reference

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

31 March 2020

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

31 March 2020

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

31 March 2020

1 reference

Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial

31 March 2020

1 reference

Peginterferon alpha/ribavirin combination therapy for the treatment of hepatitis C infection

31 March 2020

1 reference

Comparing the public health burden of chronic hepatitis C and HIV infection in France

31 March 2020

1 reference

Projecting future complications of chronic hepatitis C in the United States

31 March 2020

1 reference

Barriers to the treatment of hepatitis C. Patient, provider, and system factors

31 March 2020

1 reference

Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens.

31 March 2020

1 reference

Hepatocellular carcinoma: recent trends in Japan.

31 March 2020

1 reference

American Gastroenterological Association technical review on the management of hepatitis C.

31 March 2020

1 reference

Management of patients with chronic hepatitis C infection

31 March 2020

1 reference

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

31 March 2020

1 reference

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

31 March 2020

1 reference

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

31 March 2020

1 reference

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

31 March 2020

1 reference

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

31 March 2020

1 reference

Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]

31 March 2020

1 reference

Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.

31 March 2020

1 reference

Treating viral hepatitis C: efficacy, side effects, and complications

31 March 2020

1 reference

A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C.

31 March 2020

1 reference

A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients

31 March 2020

1 reference

Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons

31 March 2020

1 reference

Small Interfering RNA Targeted to Hepatitis C Virus 5' Nontranslated Region Exerts Potent Antiviral Effect

31 March 2020

1 reference

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

31 March 2020

1 reference

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

31 March 2020

1 reference

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

31 March 2020

1 reference

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

31 March 2020

1 reference

Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003.

31 March 2020

1 reference

The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice

31 March 2020

1 reference

Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811.

31 March 2020

1 reference

NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon

31 March 2020

1 reference

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

31 March 2020

1 reference

The nature of interferon-alpha resistance in hepatitis C virus infection

31 March 2020

1 reference

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

31 March 2020

1 reference

Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C.

31 March 2020

1 reference

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

31 March 2020

1 reference

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

31 March 2020

1 reference

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

31 March 2020

1 reference

Challenges and successes in developing new therapies for hepatitis C.

31 March 2020

1 reference

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

31 March 2020

1 reference

In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor

31 March 2020

1 reference

In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance

31 March 2020

1 reference

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

31 March 2020

1 reference

AIDS — The First 20 Years

31 March 2020

1 reference

Hepatitis C therapeutics: current status and emerging strategies

31 March 2020

1 reference

Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells

31 March 2020

1 reference

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro

31 March 2020

1 reference

Structural biology of hepatitis C virus

31 March 2020

1 reference

The hepatitis C virus replicon system: from basic research to clinical application

31 March 2020

1 reference

Unravelling hepatitis C virus replication from genome to function

31 March 2020

1 reference

The culture of designing hepato-biliary randomised trials

31 March 2020

1 reference

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

31 March 2020

1 reference

Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro

31 March 2020

1 reference

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

31 March 2020

1 reference

Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

31 March 2020

1 reference

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

31 March 2020

1 reference

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

31 March 2020

1 reference

Prospects for a vaccine against the hepatitis C virus

31 March 2020

1 reference

A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees

31 March 2020

1 reference

Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors

31 March 2020

1 reference

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus

31 March 2020

1 reference

Novel Alpha Interferon (IFN- ) Variant with Improved Inhibitory Activity against Hepatitis C Virus Genotype 1 Replication Compared to IFN- 2b Therapy in a Subgenomic Replicon System

31 March 2020

1 reference

Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD2411

1 reference

30 July 2017

1 reference